{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:04:26Z","timestamp":1793639066211,"version":"4.5.1"},"reference-count":55,"publisher":"Wiley","issue":"S3","license":[{"start":{"date-parts":[[2018,12,7]],"date-time":"2018-12-07T00:00:00Z","timestamp":1544140800000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:p>Immune\u2010deficient patients depend on the antibodies in pooled human immunoglobulin G (IgG) preparations to remain free from serious infections. The potency of IgG preparations is therefore an ongoing concern. The use of pooled IgG to prevent infection is based on the concept that healthy adults have recovered from infections earlier in life and maintain relatively high antibody titers. In general, vaccine\u2010induced immunity is less robust or long\u2010lasting than immunity after natural infection, and many infectious diseases which were formerly widely prevalent have become much less common due to improved hygiene and vaccines. This raises questions as to the adequacy of protective antibodies in current IgG preparations. This paper reviews available data on antibodies against selected bacterial and virus vaccine antigens in current IgG products. Most products contain sufficient antibody to yield levels above minimal protective concentrations to a broad range of pathogens and toxins. Illustrative examples of effects of vaccines on antibody content of IgG products are also discussed: antibody titers to hepatitis A virus in donor plasma pools in both the US and EU are dropping due to decreased natural infection, but they are still sufficient to provide robust protection. Increasing seroprevalence of hepatitis B virus as a result of immunization suggests that antibody titers against this virus may actually be increasing. Finally, serial studies suggest that pooled IgG provides protection against seasonal influenza viruses despite year\u2010to\u2010year antigenic drift, and is also likely to provide at least some protective antibody against potentially pandemic strains.<\/jats:p>","DOI":"10.1111\/trf.15017","type":"journal-article","created":{"date-parts":[[2018,12,7]],"date-time":"2018-12-07T14:18:50Z","timestamp":1544192330000},"page":"3096-3105","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Antibodies to vaccine antigens in pooled polyclonal human IgG products"],"prefix":"10.1111","volume":"58","author":[{"given":"Melvin","family":"Berger","sequence":"first","affiliation":[{"name":"Global Medical Affairs, CSL Behring, LLC  King of Prussia Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,12,7]]},"reference":[{"key":"e_1_2_8_2_1","unstructured":"United States Food and Drug Administration (2008) Guidance for industry: safety efficacy and pharmacokinetic studies to support marketing of immune globulin intravenous (human) as replacement therapy for primary humoral immunodeficiency. Available online at:https:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/GuidanceComplianceRegulatoryInformation\/Guidances\/Blood\/ucm078526.pdf"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.04.049"},{"key":"e_1_2_8_4_1","unstructured":"RH Buckley"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2010.06.012"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2012.04594.x"},{"key":"e_1_2_8_7_1","unstructured":"Immunization action coalition: immunization timeline (Updated 6\/18\/2018) [cited 2018 Aug 28]. Available from:http:\/\/www.immunize.org\/timeline\/."},{"key":"e_1_2_8_8_1","unstructured":"PapaniaM.Passive immune therapy for measles\u2014protective levels and pharmacokinetics of measles antibodies after IG infusion; pathogenesis of measles in primary immune deficient patients. 2017. In: FDA Workshop \u201cImmunoglobulin Potency in the 21stCentury\u201d Part I. p. 58\u201371. Available online athttps:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/NewsEvents\/WorkshopsMeetingsConferences\/UCM605362.pdf(Accessed 2018 Nov 28)."},{"key":"e_1_2_8_9_1","unstructured":"SimonT.Measles antibodies in donor plasma; longitudinal data and forecast. In: FDA Workshop \u201cImmunoglobulin Potency in the 21stCentury\u201d Part 1. 2017. p. 72\u201380. Available online athttps:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/NewsEvents\/WorkshopsMeetingsConferences\/UCM605362.pdf(Accessed 2018 Nov 28)."},{"key":"e_1_2_8_10_1","unstructured":"Scott D.Polio lot release specification\u2014origins and rationale. In: FDA Workshop \u201cImmunoglobulin Potency in the 21stCentury\u201d Part 1. 2017. p. 160\u20135.https:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/NewsEvents\/WorkshopsMeetingsConferences\/UCM605362.pdf(Accessed 2018 Nov 28)."},{"key":"e_1_2_8_11_1","volume-title":"Medical Microbiology","author":"Peterson JW","year":"1996"},{"key":"e_1_2_8_12_1","volume-title":"Medical Microbiology","author":"Baron S","year":"1996"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/171.6.1387"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00131-10"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.106"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1128\/.61.2.136-169.1997"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/157895"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-009-0036-6"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.2165\/00063030-200923030-00001"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a120955"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.24.2.197-202.1986"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61428-7"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15044"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.4.2.167"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15015"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15049"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.01.119"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/162.5.1036"},{"key":"e_1_2_8_29_1","unstructured":"Recommended immunization schedule for children and adolescents aged 18 years or younger United States 2018 [cited 2018 Aug 30]. Available from:https:\/\/www.cdc.gov\/vaccines\/schedules\/downloads\/child\/0-18yrs-child-combined-schedule.pdf."},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1086\/506363"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2009-0047"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.05705-11"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6705a3"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.aller.2016.04.014"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12665"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2013-1155"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-015-0131-y"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0731-7085(00)00297-1"},{"key":"e_1_2_8_39_1","first-page":"1158","article-title":"Characterization of antibodies to polysaccharide antigens of Haemophilus Influenzae type B and Streptococcus pneumoniae in human immune globulin preparations","volume":"11","author":"Mikolajczyk MG","year":"2004","journal-title":"Clin Diagn Lab Immunol"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1423-0410.2002.00186.x"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2007.11.001"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13869"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biologicals.2012.10.003"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2172-15-26"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268804002857"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2016.31.12.1937"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.09.008"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00430-008-0075-4"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1093\/milmed\/157.11.579"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1086\/429965"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701148"},{"key":"e_1_2_8_52_1","unstructured":"How the Flu Virus Can Change: \u201cDrift\u201d and \u201cShift\u201d. CDC. Available online athttps:\/\/www.cdc.gov\/flu\/about\/viruses\/change.htm(Accessed 2018 Nov 29)."},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0906453"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.08016.x"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2017.04.010"},{"key":"e_1_2_8_56_1","first-page":"23","article-title":"Neutralizing activities against seasonal influenza viruses in human intravenous immunoglobulin","volume":"11","author":"Onodera H","year":"2017","journal-title":"Biologics"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftrf.15017","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.15017","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/trf.15017","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.15017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T18:33:44Z","timestamp":1694630024000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/trf.15017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":55,"journal-issue":{"issue":"S3","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["10.1111\/trf.15017"],"URL":"https:\/\/doi.org\/10.1111\/trf.15017","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"2018-05-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}